Clinical studies targeting BCLXL in laryngeal (NCT01633541; http://clinicaltrials.gov/ct2/show/NCT01633541) and small cell lung cancer (NCT03080311) are ongoing. Here, BCL2L1 is linked to small cell lung carcinoma.